# Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

> **NCT06376084** · — · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 532 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplasms by Site
- Neoplasms
- Lung Diseases
- Respiratory Tract Diseases
- Carcinoma, Bronchogenic
- Bronchial Neoplasms

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06376084
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-23
- **Primary completion:** 2028-02-28
- **Final completion:** 2028-02-28
- **Target enrollment:** 532 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06376084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06376084, "Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06376084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*